Article Details
Retrieved on: 2021-05-22 12:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Prestige BioPharma, a Singapore-based company that has a trastuzumab biosimilar (HD201) under regulatory review, said it will build a $152 million ...
Article found on: www.centerforbiosimilars.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here